Literature DB >> 19193830

Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Maria Papp1, Istvan Altorjay, Gabriella Lakos, Judit Tumpek, Sandor Sipka, Tamas Dinya, Karoly Palatka, Gabor Veres, Miklos Udvardy, Peter Laszlo Lakatos.   

Abstract

No clear guidelines for indirect immunofluorescence (IIF) detection and interpretation of antineutrophil cytoplasmic antibodies (ANCA) have been proposed for inflammatory bowel diseases (IBD). We evaluated the reliability of the combined use of ethanol- and formalin-fixed neutrophil substrates to identify atypical perinuclear ANCA (P-ANCA) by IIF under routine laboratory circumstances. A total of 204 IBD patients were assessed with four different fluorescent substrates in two distinct laboratories. Antibodies against myeloperoxidase, proteinase-3, and other specific granule proteins (elastase, lactoferrin, cathepsin G, lysozyme, and bactericidal permeability-increasing protein) were measured by an enzyme-linked immunosorbent assay. The combined application of ethanol- and formalin-fixed slides to detect atypical P-ANCA resulted in a lack of agreement between assays (kappa, < or =0.39) in the interassay study and moderate agreement in the interobserver study (kappa, 0.42). After atypical and typical P-ANCA patterns were combined, the consensus improved greatly. A total of 26.9% of patients were P-ANCA positive by at least two tests (44.3% of ulcerative colitis [UC] and 13.1% of Crohn's disease [CD] patients; P < 0.0001), while overall ANCA positivity was 22.5% to 34.8%. The combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates did not facilitate differentiation between P-ANCA and atypical P-ANCA, and the results were not consistent when substrates from different sources were used. Combining all P-ANCA ensures the highest sensitivity and specificity in differentiating UC from CD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193830      PMCID: PMC2668288          DOI: 10.1128/CVI.00002-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  32 in total

1.  Pitfalls of formalin fixation for determination of antineutrophil cytoplasmic antibodies.

Authors:  S M Chowdhury; V Broomhead; G P Spickett; R Wilkinson
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

2.  Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives.

Authors:  A Radice; M Vecchi; M B Bianchi; R A Sinico
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

3.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.

Authors:  M Peeters; S Joossens; S Vermeire; R Vlietinck; X Bossuyt; P Rutgeerts
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

Review 4.  Anti-neutrophil antibodies in primary sclerosing cholangitis.

Authors:  B Terjung; H J Worman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-08       Impact factor: 3.043

5.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

6.  "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines.

Authors:  B Terjung; U Spengler; T Sauerbruch; H J Worman
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

7.  A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

Authors:  C Gasche; J Scholmerich; J Brynskov; G D'Haens; S B Hanauer; E J Irvine; D P Jewell; D Rachmilewitz; D B Sachar; W J Sandborn; L R Sutherland
Journal:  Inflamm Bowel Dis       Date:  2000-02       Impact factor: 5.325

8.  Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; I A Mouzas; I G Vlachonikolis; E Anagnostopoulou; E Castanas; A N Maniatis; E A Kouroumalis
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

9.  Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role.

Authors:  G Cambridge; D S Rampton; T R Stevens; D A McCarthy; M Kamm; B Leaker
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

10.  Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

Authors:  Maria Papp; Istvan Altorjay; Gary L Norman; Zakera Shums; Karoly Palatka; Zsuzsanna Vitalis; Ildiko Foldi; Gabriella Lakos; Judit Tumpek; Miklos L Udvardy; Jolan Harsfalvi; Simon Fischer; Laszlo Lakatos; Agota Kovacs; Laszlo Bene; Tamas Molnar; Zsolt Tulassay; Pal Miheller; Gabor Veres; Janos Papp; Peter Laszlo Lakatos
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

View more
  6 in total

1.  Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease.

Authors:  Maria Teresa Arias-Loste; Geovana Bonilla; Irene Moraleja; Michael Mahler; Miguel Angel Mieses; Beatriz Castro; Montserrat Rivero; Javier Crespo; Marcos López-Hoyos
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

2.  Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.

Authors:  Tamas Tornai; David Tornai; Nora Sipeki; Istvan Tornai; Rayan Alsulaimani; Kai Fechner; Dirk Roggenbuck; Gary L Norman; Gabor Veres; Gabriella Par; Alajos Par; Ferenc Szalay; Peter Laszlo Lakatos; Peter Antal-Szalmas; Maria Papp
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

3.  Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.

Authors:  Gyorgy Kovacs; Nora Sipeki; Boglarka Suga; Tamas Tornai; Kai Fechner; Gary L Norman; Zakera Shums; Peter Antal-Szalmas; Maria Papp
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

Review 4.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

Review 5.  Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases.

Authors:  Kallirroi S Kyriakidi; Vasileios E Tsianos; Evaggelos Karvounis; Dimitrios K Christodoulou; Konstantinos H Katsanos; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2016-03-24

6.  ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation.

Authors:  Naim Abu-Freha; Wafi Badarna; Ina Sigal-Batikoff; Muhammad Abu Tailakh; Ohad Etzion; Jaber Elkrinawi; Arik Segal; Alex Mushkalo; Alex Fich
Journal:  BMC Gastroenterol       Date:  2018-10-20       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.